PT3207035T - Compostos e composições para modular actividades da cinase do mutante de egfr - Google Patents

Compostos e composições para modular actividades da cinase do mutante de egfr

Info

Publication number
PT3207035T
PT3207035T PT158503144T PT15850314T PT3207035T PT 3207035 T PT3207035 T PT 3207035T PT 158503144 T PT158503144 T PT 158503144T PT 15850314 T PT15850314 T PT 15850314T PT 3207035 T PT3207035 T PT 3207035T
Authority
PT
Portugal
Prior art keywords
compositions
compounds
kinase activities
egfr mutant
mutant kinase
Prior art date
Application number
PT158503144T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55654993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3207035(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of PT3207035T publication Critical patent/PT3207035T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quick-Acting Or Multi-Walled Pipe Joints (AREA)
PT158503144T 2014-10-13 2015-10-13 Compostos e composições para modular actividades da cinase do mutante de egfr PT3207035T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462063394P 2014-10-13 2014-10-13

Publications (1)

Publication Number Publication Date
PT3207035T true PT3207035T (pt) 2020-02-19

Family

ID=55654993

Family Applications (3)

Application Number Title Priority Date Filing Date
PT158503144T PT3207035T (pt) 2014-10-13 2015-10-13 Compostos e composições para modular actividades da cinase do mutante de egfr
PT191967132T PT3604294T (pt) 2014-10-13 2015-10-13 Compostos e composições para modular atividades da cinase do mutante de egfr
PT211716196T PT3929190T (pt) 2014-10-13 2015-10-13 Compostos e composições para modular atividades da cinase do mutante de egfr

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT191967132T PT3604294T (pt) 2014-10-13 2015-10-13 Compostos e composições para modular atividades da cinase do mutante de egfr
PT211716196T PT3929190T (pt) 2014-10-13 2015-10-13 Compostos e composições para modular atividades da cinase do mutante de egfr

Country Status (30)

Country Link
US (2) US9593098B2 (OSRAM)
EP (4) EP4421069B1 (OSRAM)
JP (3) JP6524221B2 (OSRAM)
KR (5) KR102073854B1 (OSRAM)
CN (2) CN111686110B (OSRAM)
AU (1) AU2015331166B2 (OSRAM)
BR (1) BR112017007769B1 (OSRAM)
CA (1) CA2962914C (OSRAM)
CY (2) CY1122737T1 (OSRAM)
DK (3) DK3604294T3 (OSRAM)
ES (3) ES2770058T3 (OSRAM)
FI (2) FI3929190T3 (OSRAM)
FR (1) FR25C1021I1 (OSRAM)
HR (3) HRP20250213T1 (OSRAM)
HU (4) HUE048006T2 (OSRAM)
LT (4) LT3207035T (OSRAM)
MX (3) MX2017003181A (OSRAM)
NL (1) NL301329I2 (OSRAM)
NO (1) NO2025025I1 (OSRAM)
NZ (1) NZ730012A (OSRAM)
PH (1) PH12017500488A1 (OSRAM)
PL (3) PL3207035T3 (OSRAM)
PT (3) PT3207035T (OSRAM)
RS (3) RS59900B1 (OSRAM)
RU (1) RU2727700C2 (OSRAM)
SG (1) SG11201701960XA (OSRAM)
SI (3) SI3207035T1 (OSRAM)
SM (3) SMT202000059T1 (OSRAM)
TW (2) TWI730331B (OSRAM)
WO (1) WO2016060443A2 (OSRAM)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102073854B1 (ko) * 2014-10-13 2020-02-05 주식회사유한양행 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
WO2017120429A1 (en) 2016-01-07 2017-07-13 CS Pharmasciences, Inc. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
KR20220130249A (ko) * 2016-05-26 2022-09-26 리커리엄 아이피 홀딩스, 엘엘씨 Egfr 억제제 화합물
KR102030886B1 (ko) * 2016-09-23 2019-10-10 재단법인 대구경북첨단의료산업진흥재단 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
AU2018286221B2 (en) * 2017-06-13 2021-02-25 Beijing Adamadle Biotechnology Limited Liability Company Aminopyrimidine compound, preparation method therefor and use thereof
KR102684954B1 (ko) * 2017-07-28 2024-07-15 주식회사유한양행 아미노피리미딘 유도체의 합성에 유용한 신규의 중간체, 이의 제조방법 및 이를 이용한 아미노피리미딘 유도체의 제조방법
CN111315742B (zh) * 2017-07-28 2023-09-01 株式会社柳韩洋行 制备氨基嘧啶衍生物的方法
SG11201913556SA (en) * 2017-07-28 2020-02-27 Yuhan Corp Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
US11267810B2 (en) 2017-08-30 2022-03-08 Shenzhen Targetrx, Inc. Aminopyrimidine compound and composition comprising same and use thereof
CN108017633A (zh) * 2018-01-30 2018-05-11 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用
CN108047207A (zh) * 2018-01-30 2018-05-18 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺氘代物及应用
CN112955137B (zh) 2018-09-10 2025-05-13 米拉蒂治疗股份有限公司 组合疗法
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
JP7240032B2 (ja) * 2018-12-21 2023-03-15 深▲チェン▼市塔吉瑞生物医薬有限公司 プロテインキナーゼ活性を阻害するためのアミノピリミジン系化合物
SG11202108311RA (en) 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
EP3943491B1 (en) * 2019-03-19 2025-06-18 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
EA202192552A1 (ru) 2019-03-29 2021-12-17 Астразенека Аб Осимертиниб для применения в лечении немелкоклеточного рака легкого
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
MY208668A (en) 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
SG11202112412QA (en) * 2019-05-14 2021-12-30 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
CN110128354A (zh) * 2019-06-20 2019-08-16 大连大学 一种5-氟-2-甲磺酰基-4-氨基嘧啶的制备方法
KR20210032093A (ko) 2019-09-16 2021-03-24 제이투에이치바이오텍 (주) Ｅｇｆｒ 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
MX2022008874A (es) 2020-01-20 2022-08-11 Astrazeneca Ab Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer.
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202207940A (zh) 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
KR20210152312A (ko) * 2020-06-08 2021-12-15 주식회사 종근당 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물
EP4210702A1 (en) 2020-09-14 2023-07-19 JANSSEN Pharmaceutica NV Fgfr inhibitor combination therapies
TWI867047B (zh) * 2020-09-18 2024-12-21 南韓商沃若諾伊公司 雜芳基衍生物、其製備方法、及含彼作為活性成份之藥學組成物
TW202227425A (zh) * 2020-09-18 2022-07-16 南韓商沃若諾伊生物公司 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物
WO2022131741A1 (ko) * 2020-12-14 2022-06-23 보로노이바이오 주식회사 아이소옥사졸리딘 유도체 화합물 및 이의 용도
EP4335847A1 (en) * 2021-05-07 2024-03-13 Voronoi Inc. Heteroaryl derivative, method for preparing same, and pharmaceutical composition comprising same as active ingredient
JP2024519626A (ja) 2021-05-17 2024-05-21 ボロノイ インコーポレイテッド ヘテロアリール誘導体化合物およびその用途｛Ｈｅｔｅｒｏａｒｙｌ ｄｅｒｉｖａｔｉｖｅ ｃｏｍｐｏｕｎｄｓ，ａｎｄ ｕｓｅｓ ｔｈｅｒｅｏｆ｝
CN117425651A (zh) 2021-06-01 2024-01-19 杭州领业医药科技有限公司 Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
KR102685187B1 (ko) 2021-10-15 2024-07-16 제이투에이치바이오텍 (주) Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
KR20240168418A (ko) 2022-03-31 2024-11-29 아스트라제네카 아베 암 치료를 위한 akt 억제제와 조합된 표피 성장 인자 수용체(egfr) 티로신 키나아제 억제제
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
AU2023262556A1 (en) 2022-04-28 2024-12-05 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
CA3259492A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab COMBINATIONS INVOLVING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
IL318241A (en) 2022-07-08 2025-03-01 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with HGF receptor inhibitors for cancer treatment
JP2025540560A (ja) * 2022-11-03 2025-12-16 ボロノイ インコーポレイテッド Ｅｇｆｒ阻害剤のフマル酸塩、酒石酸塩、リンゴ酸塩、及びクエン酸塩
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
CN116655600B (zh) * 2023-05-23 2025-08-22 江南大学 一种取代的2-芳氨基嘧啶类化合物、药物组合物及其用途
WO2025017409A1 (en) 2023-07-14 2025-01-23 Janssen Biotech, Inc. Dosing regimen for therapies comprising bispecific antiegfr/c-met antibodies
WO2025052273A1 (en) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU725548B2 (en) 1997-03-11 2000-10-12 E.I. Du Pont De Nemours And Company Heteroaryl azole herbicides
CA2400447C (en) * 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
AP2003002825A0 (en) 2000-12-21 2003-09-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
MXPA04004178A (es) 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta.
EA200500721A1 (ru) * 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
JP4428565B2 (ja) 2004-10-05 2010-03-10 東京エレクトロン株式会社 処理液塗布装置
CN101039919A (zh) 2004-10-13 2007-09-19 惠氏公司 经n－苯磺酰基取代的苯胺基嘧啶类似物
JP5208516B2 (ja) 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
US20070072894A1 (en) 2005-03-24 2007-03-29 Kempf J V Synthesis of pyrroloquinoline quinone (PQQ)
JP5007029B2 (ja) 2005-07-13 2012-08-22 Ｎｔｎ株式会社 グリース組成物および該グリース封入転がり軸受
KR101011958B1 (ko) 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 ｐ38 ＭＡＰ 키나아제 저해제로서의 융합형 피라졸
JP2007117465A (ja) 2005-10-28 2007-05-17 Sharp Corp 集塵器およびそれを備えた電気掃除機
GB2450046B (en) 2006-03-29 2011-03-09 Kt Freetel Co Ltd Digital device and method for providing additional service by using the same
US8008481B2 (en) 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
AU2007238897A1 (en) 2006-04-12 2007-10-25 Wyeth Anilino-pyrimidine phenyl and benzothiophene analogs
US7687522B2 (en) 2006-12-20 2010-03-30 Amgen Inc. Substituted pyridines and pyrimidines and their use in treatment of cancer
NZ589843A (en) 2008-06-27 2012-12-21 Avila Therapeutics Inc Pyrimidine heteroaryl compounds and uses thereof as protein kinase inhibitors
JP5918693B2 (ja) * 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
KR101663637B1 (ko) 2009-11-13 2016-10-07 제노스코 키나아제 억제제
IN2013MN01519A (OSRAM) 2011-02-25 2015-06-12 Yuhan Corp
CN105175396B (zh) 2011-07-27 2018-01-16 阿斯利康(瑞典)有限公司 取代的4‑甲氧基‑n3‑(嘧啶‑2‑基)苯‑1,3‑二胺化合物及其盐
WO2013109882A1 (en) 2012-01-20 2013-07-25 Genosco Substituted pyrimidine compounds and their use as syk inhibitors
WO2014040555A1 (zh) * 2012-09-12 2014-03-20 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
US10273224B2 (en) * 2013-08-22 2019-04-30 Jubilant Biosys Limited Substituted pyrimidine compounds, compositions and medicinal applications thereof
WO2015094803A1 (en) 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
CN106660993B (zh) * 2014-06-12 2020-09-11 上海复尚慧创医药研究有限公司 一类激酶抑制剂
GEP20207111B (en) 2014-06-19 2020-05-25 Ariad Pharma Inc Heteroaryl compounds for kinase inhibition
KR102073854B1 (ko) * 2014-10-13 2020-02-05 주식회사유한양행 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用

Also Published As

Publication number Publication date
USRE50528E1 (en) 2025-08-12
LTPA2025522I1 (OSRAM) 2025-06-25
WO2016060443A2 (en) 2016-04-21
ES2879474T3 (es) 2021-11-22
PT3929190T (pt) 2025-02-19
LT3604294T (lt) 2021-07-26
RS66529B1 (sr) 2025-03-31
PT3604294T (pt) 2021-07-29
KR102073854B1 (ko) 2020-02-05
US9593098B2 (en) 2017-03-14
EP4421069A1 (en) 2024-08-28
LT3929190T (lt) 2025-02-25
AU2015331166B2 (en) 2018-04-26
KR20230010836A (ko) 2023-01-19
HUE070874T2 (hu) 2025-07-28
KR20200014944A (ko) 2020-02-11
DK3207035T3 (da) 2020-01-27
HUE048006T2 (hu) 2020-05-28
BR112017007769A2 (pt) 2018-01-16
KR20170066650A (ko) 2017-06-14
DK3604294T3 (da) 2021-06-28
CY1122737T1 (el) 2021-03-12
RU2727700C2 (ru) 2020-07-23
TWI730331B (zh) 2021-06-11
CN106795144A (zh) 2017-05-31
SI3604294T1 (sl) 2021-08-31
AU2015331166A1 (en) 2017-03-30
WO2016060443A3 (en) 2016-06-23
JP2017530999A (ja) 2017-10-19
EP3604294A1 (en) 2020-02-05
SMT202500069T1 (it) 2025-03-12
RS59900B1 (sr) 2020-03-31
SMT202100266T1 (it) 2021-07-12
LT3207035T (lt) 2020-02-25
KR20210011068A (ko) 2021-01-29
JP6754864B2 (ja) 2020-09-16
CN111686110B (zh) 2023-06-16
JP2020196740A (ja) 2020-12-10
FI3929190T3 (fi) 2025-02-28
FR25C1021I1 (fr) 2025-08-01
FIC20250023I1 (fi) 2025-06-06
CY1124359T1 (el) 2022-07-22
EP4421069B1 (en) 2025-12-10
HRP20210949T1 (hr) 2021-09-03
EP3929190A1 (en) 2021-12-29
EP3207035A2 (en) 2017-08-23
HRP20200201T1 (hr) 2020-05-15
DK3929190T3 (da) 2025-02-24
HUS2500023I1 (hu) 2025-06-28
RU2020123547A (ru) 2020-08-18
JP2019163277A (ja) 2019-09-26
EP3929190B1 (en) 2024-12-25
KR102208775B1 (ko) 2021-01-28
SMT202000059T1 (it) 2020-03-13
CA2962914C (en) 2018-10-23
US20160102076A1 (en) 2016-04-14
RS61865B1 (sr) 2021-06-30
TW201938553A (zh) 2019-10-01
RU2017116598A3 (OSRAM) 2018-11-21
RU2017116598A (ru) 2018-11-21
SI3207035T1 (sl) 2020-04-30
MX2020002168A (es) 2021-09-07
KR20240074820A (ko) 2024-05-28
BR112017007769B1 (pt) 2023-10-10
EP3604294B1 (en) 2021-05-05
EP3207035A4 (en) 2018-03-14
KR102662358B1 (ko) 2024-04-30
NL301329I2 (nl) 2025-09-09
PL3929190T3 (pl) 2025-06-09
ES2770058T3 (es) 2020-06-30
KR102487451B1 (ko) 2023-01-11
PH12017500488A1 (en) 2017-07-31
JP6524221B2 (ja) 2019-06-05
SG11201701960XA (en) 2017-04-27
HRP20250213T1 (hr) 2025-04-25
MX2021010761A (es) 2022-06-09
MX385942B (es) 2025-03-18
CN106795144B (zh) 2020-06-16
NZ730012A (en) 2019-06-28
EP3207035B1 (en) 2019-11-20
TW201619150A (zh) 2016-06-01
PL3207035T3 (pl) 2020-06-01
PL3604294T3 (pl) 2021-11-02
CA2962914A1 (en) 2016-04-21
CN111686110A (zh) 2020-09-22
NO2025025I1 (no) 2025-06-05
HUE054848T2 (hu) 2021-09-28
ES3009926T3 (en) 2025-03-31
MX2017003181A (es) 2017-07-20
TWI664173B (zh) 2019-07-01
SI3929190T1 (sl) 2025-04-30

Similar Documents

Publication Publication Date Title
HUS2500023I1 (hu) Vegyületek és készítmények EGFR mutáns kináz aktivitás modulására
IL286669A (en) Compounds and methods for modulating tmprss6 expression
IL273058A (en) Compositions and methods for modulation of PKK expression
ZA201801600B (en) Compounds and methods for modulating angiotensinogen expression
SG11201802798WA (en) Compounds, compositions, and methods for modulating cftr
IL252554A0 (en) A history of mutated 2-anilinopyrimidines as egfr modulators
IL246879B (en) Preparations of Epilimod and methods of using them
ZA201700021B (en) Alk kinase inhibitor, and preparation method and use thereof
PL3114282T3 (pl) Mieszana murawa
PT3113774T (pt) Composições de grapiprant e métodos de utilização das mesmas
SG10202003691PA (en) Composition for modulating irak1
GB201614961D0 (en) Compounds and compositions for use
GB201409661D0 (en) Novel compounds and their use as kinase inhibitors
GB201405532D0 (en) Novel compounds and their use as Kinase inhibitors